The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study-Reference-Cited by-同舟云学术

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study

Published:2011-01 Issue:1 Volume:9 Page:226-228
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

TRIPODI A.,CHANTARANGKUL V.,GUINET C.,SAMAMA M. M.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2010.04106.x/fullpdf

Reference8 articles.

1. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery;Mueck;Clin Pharmacokinet,2008

2. New oral antithrombotics: a need for laboratory monitoring.;Mismetti;J Thromb Haemost,2010

3. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor;Samama;Thromb Haemost,2010

4. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy;van den Besselaar;World Health Organ Tech Rep Ser,1999

5. Thromboplastin composition controls the sensitivity of prothrombin time (PT) clotting tests to rivaroxaban, a direct factor Xa inhibitor;Smith;Blood,2007

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization of international normalized ratio‐derived formula to predict plasma rivaroxaban level—Validation study and real‐world experience;International Journal of Laboratory Hematology;2024-07-17

2. CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30

3. The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases;Scientific Reports;2024-02-19

4. Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, S.A.V.) vs Rivaroxaban 20 Mg (Bayer Laboratories) on Prothrombin Time;International Journal of Clinical Medicine;2024

5. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-12-19